RT Journal Article
SR Electronic
T1 Impaired glucose metabolism in patients with diabetes, prediabetes and obesity is associated with severe Covid-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.04.20122507
DO 10.1101/2020.06.04.20122507
A1 Stephen M. Smith
A1 Avinash Boppana
A1 Julie A. Traupman
A1 Enrique Unson
A1 Daniel A. Maddock
A1 Kathy Chao
A1 David P. Dobesh
A1 Ruth I. Connor
YR 2020
UL http://medrxiv.org/content/early/2020/06/05/2020.06.04.20122507.abstract
AB Background Identification of risk factors of severe Covid-19 is critical for improving therapies and understanding SARS-CoV-2 pathogenesis.Methods We analyzed 184 patients hospitalized for Covid-19 in Livingston, New Jersey for clinical characteristics associated with severe disease.Results The majority of Covid-19 patients had diabetes mellitus (DM) (62.0%), Pre-DM (23.9%) with elevated FBG, or a BMI > 30 with normal HbA1C (4.3%). SARS-CoV-2 infection was associated with new and persistent hyperglycemia in 29 patients, including several with normal HbA1C levels. Forty-four patients required intubation, which occurred significantly more often in patients with DM as compared to non-diabetics.Conclusions Severe Covid-19 occurs in the presence of impaired glucose metabolism in patients with SARS-CoV-2 infection. The association of dysregulated glucose metabolism and severe Covid-19 suggests a previously unrecognized manifestation of primary SARS-CoV-2 infection. Exploration of pathways by which SARS-CoV-2 impacts glucose metabolism is critical for understanding disease pathogenesis and developing therapies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Saint Barnabas Medical Center IRB approved this study, IRB number 20-19.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI can make the data available in spreadsheet format on Google.